13 Abr Compounds with potent antiparasitic activity and improved pharmaco-kinetics properties.
[/one_fourth][three_fourth_last][box]CSIC has developed a family of compounds characterized by the presence of a triphenylphosphonium cation which significantly increases their antiparasitic activity. These compounds show antitrypanosomal activity, with in vitro values higher than those of known reference drugs. Therefore, these compounds are excellent candidates for the treatment of parasitic diseases such as human African trypanosomiasis (HAT), animal trypanosomiasis and Cryptosporidium parvum infections. Pharmaceutical companies interested in a patent licence are sought for.[/box]